JAMA Neurology Publishes Landmark Study Showing Neuropacs™ AI Technology Significantly Enhances the Diagnostic Accuracy of Parkinson’s Disease and Atypical Parkinsonism

UF startup neuropacs™ Corp., a leading innovator in AI-driven neurological diagnostics, announces the results of a prospective multicenter study that evaluated neuropacs™ AI technology for diagnosing Parkinson’s disease and atypical parkinsonism. The study was published in JAMA Neurology (doi: 10.1001/jamaneurol.2025.0112) and funded by grant U01NS119562 from the National Institutes of Health (National Institute of Neurological Disorders and Stroke).

The study “Prospective Multicenter Study of Automated Imaging Differentiation for Parkinsonism” evaluated the diagnostic accuracy of neuropacs™ AI technology in 249 patients across 21 movement disorders centers of the Parkinson’s Study Group in the United States and Canada. Diffusion MRI scans were acquired in patients using Siemens, General Electric, and Philips 3T scanners. The MRI scans were used in the neuropacs™ AI software to predict the clinical diagnosis.

Read more about JAMA Neurology Publishes Landmark Study Showing Neuropacs™ AI Technology Significantly Enhances the Diagnostic Accuracy of Parkinson’s Disease and Atypical Parkinsonism.